Literature DB >> 12215176

Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future.

Fergus Shanahan1.   

Abstract

Probiotic therapy is attracting the renewed interest of clinicians and basic investigators from a variety of traditional research disciplines. While the theoretical rationale for modifying the commensal flora of the gastrointestinal tract in specific circumstances appears sound and requires scientific pursuit, the field of probiotics has been clouded by exaggerated claims from some quarters. In general, many of the claims for therapeutic efficacy have not been well substantiated, but the field is now poised for evaluation within the realm of evidence-based medicine. Alterations in commensal bacterial flora within the gastrointestinal tract are associated with susceptibility to pathogens such as Clostridium difficile and there is persuasive evidence that the normal flora may participate in the pathogenesis of inflammatory bowel disease and other chronic diseases in genetically susceptible individuals. This has prompted various strategies to fortify or otherwise modify the enteric flora by dietary supplements containing probiotic formulations. Detailed comparisons of probiotic performance amongst different bacterial strains have not been performed in vivo in man or under clinical trial conditions, and the level of scientific characterisation of individual organisms has been variable. In addition, it cannot be assumed that the same probiotic is equally suitable for all individuals. Moreover, the heterogeneity of clinical disorders such as Crohn's disease and ulcerative colitis implies that strain-specific properties may be required for subset-specific categories of patients. While cocktails of probiotics offer convenience, therapeutic progress may require clarification of the mechanism of probiotic action and may be delayed until individual bacterial components have been rigorously studied. More importantly, the full potential of therapeutic manipulation of the enteric flora with probiotics or other strategies may not be optimally realised until the composition and metabolic activities of the normal flora are better understood.

Entities:  

Mesh:

Year:  2002        PMID: 12215176     DOI: 10.1079/BJN2002624

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  14 in total

1.  The emerging therapeutic role of probiotics in inflammatory bowel disease.

Authors:  Matthew Chandler; Eric Wollins; Anastasia Toles; Marie Borum; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-09

2.  Lactobacillus rhamnosus GG treatment improves intestinal permeability and modulates inflammatory response and homeostasis of spleen and colon in experimental model of Pseudomonas aeruginosa pneumonia.

Authors:  Ludmila Khailova; Christine H Baird; Aubri A Rush; Christopher Barnes; Paul E Wischmeyer
Journal:  Clin Nutr       Date:  2016-10-01       Impact factor: 7.324

3.  Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock.

Authors:  Misha D Luyer; Wim A Buurman; M'hamed Hadfoune; Gea Speelmans; Jan Knol; Jan A Jacobs; Cornelis H C Dejong; Aldwin J M Vriesema; Jan Willem M Greve
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

4.  Survival of probiotic lactobacilli in acidic environments is enhanced in the presence of metabolizable sugars.

Authors:  B M Corcoran; C Stanton; G F Fitzgerald; R P Ross
Journal:  Appl Environ Microbiol       Date:  2005-06       Impact factor: 4.792

5.  Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects.

Authors:  Benoit Foligné; Sophie Nutten; Lothar Steidler; Véronique Dennin; Denise Goudercourt; Annick Mercenier; Bruno Pot
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

6.  Nutritional Therapy in Inflammatory Bowel Disease.

Authors:  Maria O'Sullivan; Colm O'Morain
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06

7.  Dichotomy between Lactobacillus rhamnosus and Klebsiella pneumoniae on dendritic cell phenotype and function.

Authors:  Henri Braat; Esther C de Jong; Jan M H van den Brande; Martien L Kapsenberg; Maikel P Peppelenbosch; Eric A F van Tol; Sander J H van Deventer
Journal:  J Mol Med (Berl)       Date:  2003-12-13       Impact factor: 4.599

8.  Probiotic administration reduces mortality and improves intestinal epithelial homeostasis in experimental sepsis.

Authors:  Ludmila Khailova; Daniel N Frank; Jessica A Dominguez; Paul E Wischmeyer
Journal:  Anesthesiology       Date:  2013-07       Impact factor: 7.892

9.  Lactobacillus rhamnosus GG improves outcome in experimental pseudomonas aeruginosa pneumonia: potential role of regulatory T cells.

Authors:  Ludmila Khailova; Christine H Baird; Aubri A Rush; Eoin N McNamee; Paul E Wischmeyer
Journal:  Shock       Date:  2013-12       Impact factor: 3.454

10.  Prevention and treatment of urinary tract infection with probiotics: Review and research perspective.

Authors:  D Borchert; L Sheridan; A Papatsoris; Z Faruquz; J M Barua; I Junaid; Y Pati; F Chinegwundoh; N Buchholz
Journal:  Indian J Urol       Date:  2008-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.